Daniel G. Polhamus, Ph.D

Group Leader Statistics, Principal Scientist II

Dan joined Metrum in September, 2010 and is an applied statistician with an emphasis on Bayesian biostatistics, clinical trial design, and high performance statistical computing. His dissertation topic was adaptive design for heterogeneous time-to-event data in a Bayesian decision theory framework.

Recent publications by this scientist

Population exposure–response analysis supports efficacy outcomes of garadacimab in patients with hereditary angioedema

June 26, 2024

Presented at ASCPT Annual Meeting 2024. Garadacimab (anti-activated factor XII monoclonal antibody) demonstrated efficacy for the prevention of hereditary angioedema (HAE) attacks with a favorable safety profile in Phase 2, pivotal Phase 3 (VANGUARD), and Phase 3 open-label extension studies. In this exposure-response (ER) analysis, the efficacy of garadacimab and effect of covariates on attack rate (number of attacks/month) were assessed to support garadacimab dosing in patients with HAE.

Read Article

Exposure–efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn’s disease and ulcerative colitis

March 6, 2024

This posthoc analysis of the GEMINI and VISIBLE studies in ulcerative colitis (UC) and Crohn’s Disease (CD) assessed exposure−efficacy of vedolizumab intravenous (IV) and subcutaneous (SC).

Read Article

Exposure-Safety Markov Modeling of Ocular Adverse Events in Patient Populations Treated With Tisotumab Vedotin

July 24, 2023

The current analysis aimed to characterize exposure-response relationships of TV exposure on the incidence, severity, and longitudinal time course of grade ≥2 ocular adverse events (AEs).

Download PDF